Stock IMNN IMUNON, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Imunon, Inc. Stock

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 04:00:00 2025-01-17 pm EST 		5-day change 1st Jan Change
0.9131 USD +1.68% Intraday chart for Imunon, Inc. +1.47% -3.88%
Dec. 19 IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer CI
Dec. 10 Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001 CI

Valuation: Imunon, Inc.

Capitalization 13.24M 12.87M 12.1M 10.86M 19.07M 1.15B 21.31M 148M 54.76M 471M 49.65M 48.64M 2.07B P/E ratio 2024 *
-0.54x
P/E ratio 2025 * -0.88x
Enterprise value 13.24M 12.87M 12.1M 10.86M 19.07M 1.15B 21.31M 148M 54.76M 471M 49.65M 48.64M 2.07B EV / Sales 2024 *
-
EV / Sales 2025 * -
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Imunon, Inc.

Dynamic Chart

Latest news: Imunon, Inc.

IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer Dec. 19 CI
Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001 Dec. 10 CI
Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer Nov. 25 CI
Imunon, Inc., Q3 2024 Earnings Call, Nov 07, 2024 Nov. 07
IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001 Nov. 07 CI
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 07 CI
IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting 24-10-30 CI
Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary 24-10-07 CI
Imunon Files for Stock Resale by Security Holders 24-08-29 MT
Imunon, Inc. announced that it has received $10 million in funding 24-08-15 CI
Imunon, Inc., Q2 2024 Earnings Call, Aug 14, 2024 24-08-14
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 24-08-14 CI
Imunon, Inc. announced that it expects to receive $10 million in funding 24-07-31 CI
More news

Last Transcript: Imunon, Inc.

Logo Imunon, Inc.
Imunon, Inc., Q3 2024 Earnings Call, Nov 07, 2024
Nov. 07
More transcripts

Analysts' recommendations: Imunon, Inc.

HC Wainwright Adjust Price Target on Imunon to $13 From $12, Keeps Buy Rating 24-04-01 MT
Alliance Global Starts Imunon at Buy with $15 Price Target 22-10-13 MT
HC Wainwright Starts Celsion at Buy With $16 Price Target 22-04-13 MT
More recommendations

Press Releases: Imunon, Inc.

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer Dec. 19 AQ
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 Dec. 10 AQ
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer Nov. 25 AQ
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting Nov. 07 AQ
IMUNON : Reports Third Quarter 2024 Financial Results and Provides Business Updates Form 8 K Nov. 07 PU
More press releases

News in other languages: Imunon, Inc.

Euroapi: Mattias Perjos, PDG de Getinge, nouvel administrateur indépendant 23-01-12
Euroapi : cooptation d'un nouvel administrateur 23-01-12
Alcoa : MÄRKTE USA/Nach neuen Hochs geht Wall Street die Luft aus 21-01-21
More news

Quotes and Performance

1 day+1.68%
1 week+1.47%
Current month-3.88%
1 month+6.90%
3 months-7.35%
6 months-26.95%
Current year-3.88%
More quotes

Course Extremes

1 week
0.87
Extreme 0.872
0.93
1 month
0.76
Extreme 0.7609
1.08
Current year
0.84
Extreme 0.8428
1.08
1 year
0.48
Extreme 0.48
3.65
3 years
0.48
Extreme 0.48
7.80
5 years
0.48
Extreme 0.48
97.50
10 years
0.48
Extreme 0.48
749.71
More quotes

Managers and Directors: Imunon, Inc.

Director TitleAgeSince
Stacy Lindborg CEO
 Chief Executive Officer 54 2024-05-12
David Gaiero DFI
 Director of Finance/CFO 46 2024-05-31
Sebastien Hazard CTO
 Chief Tech/Sci/R&D Officer 54 2023-12-10
Manager TitleAgeSince
Michael Tardugno CHM
 Chairman 74 2014-10-06
Frederick Fritz BRD
 Director/Board Member 74 2011-07-07
Donald Braun BRD
 Director/Board Member 75 2015-12-14
More insiders

ETFs: Imunon, Inc.

Name Weight AuM 1st Jan change Investor Rating
VANGUARD US TOTAL MARKET SHARES INDEX ETF ETF Vanguard US Total Market Shares Index ETF
0.00% 293,477 M€ +1.79% -
More ETFs: Imunon, Inc.

Bio Therapeutic Drugs

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
IMUNON, INC. Stock Imunon, Inc.
+1.68%+1.47%+60.19%-85.92%13.24M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+1.21%+3.04%-2.99%+82.81%109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
-1.68%-2.20%-26.98%+10.27%73.33B
ARGENX SE Stock argenx SE
-0.69%-2.07%+89.13%+148.78%39.62B
BIONTECH SE Stock BioNTech SE
-0.74%-8.89%+13.96%-30.76%26.83B
BEIGENE, LTD. Stock BeiGene, Ltd.
+2.31%+18.88%+31.48%-11.30%22.39B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
+5.72%+5.00%-25.18%-49.97%20.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.94%+1.67%+4.29%+96.70%14.5B
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
+4.62%+6.61%+427.15%+749.55%14.03B
GENMAB A/S Stock Genmab A/S
-0.03%-3.20%-23.10%-34.62%13.23B
Average +1.33%+1.54%+54.79%+87.55% 33.33B
Weighted average by Cap. +0.63%+1.17%+22.62%+75.00%
See all sector performances

Financials

2024 *2025 *
Net sales - -
Net income -20.48M -19.9M -18.72M -16.8M -29.5M -1.77B -32.95M -229M -84.68M -728M -76.79M -75.22M -3.2B -27.42M -26.64M -25.06M -22.49M -39.5M -2.37B -44.12M -306M -113M -975M -103M -101M -4.29B
Net Debt - -
More financial data * Estimated data

Company Profile

Logo Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
Employees
33
Sector
Biotechnology & Medical Research
Calendar
2025-03-26 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
25-01-17 0.9131 $ +1.68% 84,811
25-01-16 0.8980 $ +0.91% 36,103
25-01-15 0.8899 $ -0.40% 93,385
25-01-14 0.8935 $ -2.47% 43,822
25-01-13 0.9161 $ +1.80% 138,943

Delayed Quote Nasdaq, January 17, 2025 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart IMUNON-INC More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9131USD
Average target price
13.20USD
Spread / Average Target
+1,345.62%
Consensus
Profit revisions
estimates-change-chart IMUNON-INC Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart IMUNON-INC Company calendar
  1. Stock Market
  2. Equities
  3. IMNN Stock